Lensar, Inc. (LNSR)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1320350 · fiscal year ends in Dec
Closing price $5.83 on 30 Oct 2026; 52-week range $5.01 to $12.73.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $60.3M
- Revenue growth
- 3.3%
- Net income, last twelve months
- $34.7M
- Earnings per share
- -$0.33
- Gross margin
- 48.3%
- Operating margin
- -13.5%
- Net margin
- 57.6%
- Return on equity
- 232.8%
- Market value
- $71.7M
- Cash
- $13.6M
- Debt
- $3.8M
- Debt to equity
- 0.25
- Shares outstanding
- 12.3M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $58.4M | -$24.6M | -$34.3M | -$2.87 | -$14.9M | 10-K filed 31 Mar 2026 |
| FY2024 | 31 Dec 2024 | $53.5M | -$10.7M | -$31.4M | -$2.73 | -$2.4M | 10-K filed 27 Feb 2025 |
| FY2023 | 31 Dec 2023 | $42.2M | -$12.2M | -$14.4M | -$1.31 | -$9.9M | 10-K filed 4 Mar 2024 |
| FY2022 | 31 Dec 2022 | $35.4M | -$20.2M | -$19.9M | -$1.96 | -$15.0M | 10-K filed 16 Mar 2023 |
| FY2021 | 31 Dec 2021 | $34.5M | -$19.7M | -$19.6M | -$2.09 | -$9.3M | 10-K filed 3 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $16.5M | $3.5M | $0.10 |
| Q1 FY2026 | 31 Mar 2026 | $13.4M | $36.3M | $0.00 |
| Q4 FY2025 | 31 Dec 2025 | $16.0M | -$1.5M | -$0.12 |
| Q3 FY2025 | 30 Sep 2025 | $14.3M | -$3.7M | -$0.31 |
| Q2 FY2025 | 30 Jun 2025 | $13.9M | -$1.8M | -$0.15 |
| Q1 FY2025 | 31 Mar 2025 | $14.2M | -$27.3M | -$2.32 |
| Q4 FY2024 | 31 Dec 2024 | $16.7M | -$18.7M | -$1.61 |
| Q3 FY2024 | 30 Sep 2024 | $13.5M | -$1.5M | -$0.13 |
Company events
The newest 8-K filings of 59 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 13 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 10 Aug 2026 | 8-K | Shareholder vote | 5.07 |
| 29 May 2026 | 8-K | Leadership change, Director nominations, Other events | 5.02, 5.08, 8.01 |
| 8 May 2026 | 8-K | Results | 2.02, 9.01 |
| 15 Apr 2026 | 8-K | Leadership change | 5.02 |
| 31 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 17 Mar 2026 | 8-K | Material agreement, Agreement ended, Investor update | 1.01, 1.02, 7.01, 9.01 |
| 13 Mar 2026 | 8-K/A | Other events | 8.01 |
| 12 Mar 2026 | 8-K | Other events | 8.01 |
| 25 Feb 2026 | 8-K | Investor update | 7.01, 9.01 |
| 19 Dec 2025 | 8-K | Shareholder vote | 5.07 |
| 6 Nov 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 171 held.
| Filed | Form | Period |
|---|---|---|
| 13 Aug 2026 | 10-Q | 30 Jun 2026 |
| 13 Aug 2026 | 8-K | 13 Aug 2026 |
| 10 Aug 2026 | 8-K | 4 Aug 2026 |
| 23 Jun 2026 | DEFA14A | – |
| 23 Jun 2026 | ARS | 31 Dec 2025 |
| 23 Jun 2026 | DEF 14A | 23 Jun 2026 |
| 2 Jun 2026 | S-8 | – |
| 29 May 2026 | 8-K | 25 May 2026 |
| 8 May 2026 | 10-Q | 31 Mar 2026 |
| 8 May 2026 | 8-K | 8 May 2026 |
| 30 Apr 2026 | 10-K/A | 31 Dec 2025 |
| 15 Apr 2026 | 8-K | 10 Apr 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 12 May 2026 | STAAB THOMAS R II, Officer | 850 | $4.9K | 12 May 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 29 Jul 2026 | BlackRock, Inc. | 13G amended | 1.5% | 184.1K |
| 14 May 2026 | BRANDES INVESTMENT PARTNERS, LP | 13G amended | 8.5% | 1.0M |
| 13 Nov 2025 | BRANDES INVESTMENT PARTNERS, LP | 13G | 6.5% | 778.1K |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 307.0K | -4.79% | 8.05 |
| 30 Sep 2026 | 322.4K | -4.68% | 6.57 |
| 15 Sep 2026 | 338.2K | -11.45% | 4.27 |
| 31 Aug 2026 | 381.9K | -8.06% | 3 |
| 14 Aug 2026 | 415.4K | -7.9% | 1.49 |
| 31 Jul 2026 | 451.1K | -6.64% | 12.17 |
| 15 Jul 2026 | 483.2K | -4.41% | 10.99 |
| 30 Jun 2026 | 505.4K | -45.75% | 2.73 |
Funds that hold it
From each fund's latest Form 13F.
104 funds held it at 30 Jun 2026: 35 added and 20 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Brandes Investment Partners, LP | 1,075,400 | $6.1M | +50,224 |
| Vanguard Capital Management LLC | 402,806 | $2.3M | +12,716 |
| Groupe la Francaise | 213,537 | $1.2M | 0 |
| RBF Capital, LLC | 188,661 | $1.1M | +143,134 |
| BlackRock, Inc. | 185,033 | $1.1M | -443,715 |
| CSS LLC | 163,450 | $933.3K | 0 |
| Dimensional Fund Advisors LP | 151,609 | $865.7K | -73,325 |
| Credit Industriel Et Commercial | 144,359 | $824.3K | 0 |
| Kerrisdale Advisers, LLC | 139,390 | $795.9K | 0 |
| Millennium Management LLC | 120,680 | $689.1K | +108,115 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B